Who are Placebo to omarigliptin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sitagliptin combined with metformin, sitagliptin and acarbose, Metformin and Saxagliptin, DPP-4 inhibitor + metformin group, exenatide and sitagliptin, Sitagliptin (Januvia).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-omarigliptin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo to omarigliptin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo to omarigliptin (Placebo to omarigliptin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor. Area: Diabetes.

phase 3 DPP-4 inhibitor DPP-4 (dipeptidyl peptidase-4) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to omarigliptin (Placebo to omarigliptin) — Merck Sharp & Dohme LLC. Omarigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to stimulate insulin secretion and reduce glucagon in response to elevated blood glucose.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo to omarigliptin TARGET	Placebo to omarigliptin	Merck Sharp & Dohme LLC	phase 3	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)
Sitagliptin combined with metformin	Sitagliptin combined with metformin	Sun Yat-sen University	marketed	DPP-4 inhibitor combined with biguanide	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I
sitagliptin and acarbose	sitagliptin and acarbose	Nanjing First Hospital, Nanjing Medical University	marketed	DPP-4 inhibitor + alpha-glucosidase inhibitor combination	DPP-4 enzyme; alpha-glucosidase enzymes
Metformin and Saxagliptin	Metformin and Saxagliptin	ikfe-CRO GmbH	marketed	Biguanide + DPP-4 inhibitor combination	Metformin: mitochondrial glycerophosphate dehydrogenase; Saxagliptin: DPP-4 (dipeptidyl peptidase-4)
DPP-4 inhibitor + metformin group	DPP-4 inhibitor + metformin group	Beni-Suef University	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial glycerophosphate dehydrogenase
exenatide and sitagliptin	exenatide and sitagliptin	AstraZeneca	marketed	GLP-1 receptor agonist and DPP-4 inhibitor combination	GLP-1 receptor (exenatide); DPP-4 (sitagliptin)
Sitagliptin (Januvia)	Sitagliptin (Januvia)	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	marketed	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor class)

Merck Sharp & Dohme LLC · 5 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
AstraZeneca · 4 drugs in this class
LG Life Sciences · 2 drugs in this class
Tanabe Pharma Corporation · 2 drugs in this class
Ain Shams University · 2 drugs in this class
Ono Pharmaceutical Co. Ltd · 2 drugs in this class
Cinnagen · 1 drug in this class
GRADE Study Group · 1 drug in this class
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to omarigliptin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-omarigliptin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab